Abivax S.A. (ABVX) Form 424B5 — Jun 30, 2026
Abivax S.A. has filed a preliminary prospectus supplement for a public offering of $600 million in American Depositary Shares to fund the commercialization of its lead drug candidate obefazimod and ongoing clinical research and development expenses. This capital raise follows the company’s announcement of positive topline results from Part 2 of its Phase 3 ABTECT maintenance trial in ulcerative colitis, supporting a planned New Drug Application submission in the fourth quarter of 2026.
Key figures
- Total Debt
- 1665000
- Cash Position
- 503941000
- Deal Value Usd
- 600,000,000
- Shares Issued Repurchase
- 403347
- Royalty Repurchase Cash Usd
- 45,000,000
- Royalty Repurchase Total Usd
- 90,000,000
Price after filing
Close on the filing date to close N calendar days later (from $133.26). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.